View in EDS

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Saved in:
Bibliographic Details
Title: Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Authors: Lu H; Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Claggett BL; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Vaduganathan M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Desai AS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Jhund PS; British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom., Voors AA; Department of Cardiology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands., Senni M; University of Milano-Bicocca, Milan, Italy; Papa Giovanni XXIII Hospital, Bergamo, Italy., Zannad F; Université de Lorraine, Inserm Clinical Investigation Centre, CHU, Nancy, France., Pitt B; School of Medicine, University of Michigan, Ann Arbor, Michigan, USA., Shah SJ; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Lam CSP; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore., Scheerer MF; Bayer AG, Global Medical Affairs, Berlin, Germany., Scalise A; Cardiology and Nephrology Clinical Development, Bayer Hispania S.L., Barcelona, Spain., Mueller K; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany., Berger M; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany., Goea L; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany., McMurray JJV; British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom., Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ssolomon@bwh.harvard.edu.
Source: JACC. Heart failure [JACC Heart Fail] 2025 Oct; Vol. 13 (10), pp. 102590. Date of Electronic Publication: 2025 Aug 25.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1787 (Electronic) Linking ISSN: 22131779 NLM ISO Abbreviation: JACC Heart Fail Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40857999
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lu+H%22">Lu H</searchLink>; Division of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Claggett+BL%22">Claggett BL</searchLink>; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Vaduganathan+M%22">Vaduganathan M</searchLink>; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Desai+AS%22">Desai AS</searchLink>; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Jhund+PS%22">Jhund PS</searchLink>; British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Voors+AA%22">Voors AA</searchLink>; Department of Cardiology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Senni+M%22">Senni M</searchLink>; University of Milano-Bicocca, Milan, Italy; Papa Giovanni XXIII Hospital, Bergamo, Italy.<br /><searchLink fieldCode="AU" term="%22Zannad+F%22">Zannad F</searchLink>; Université de Lorraine, Inserm Clinical Investigation Centre, CHU, Nancy, France.<br /><searchLink fieldCode="AU" term="%22Pitt+B%22">Pitt B</searchLink>; School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.<br /><searchLink fieldCode="AU" term="%22Shah+SJ%22">Shah SJ</searchLink>; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Lam+CSP%22">Lam CSP</searchLink>; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Scheerer+MF%22">Scheerer MF</searchLink>; Bayer AG, Global Medical Affairs, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Scalise+A%22">Scalise A</searchLink>; Cardiology and Nephrology Clinical Development, Bayer Hispania S.L., Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Mueller+K%22">Mueller K</searchLink>; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Berger+M%22">Berger M</searchLink>; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Goea+L%22">Goea L</searchLink>; Bayer AG, Pharmaceuticals, R&D, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22McMurray+JJV%22">McMurray JJV</searchLink>; British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Solomon+SD%22">Solomon SD</searchLink>; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ssolomon@bwh.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101598241%22">JACC. Heart failure</searchLink> [JACC Heart Fail] 2025 Oct; Vol. 13 (10), pp. 102590. <i>Date of Electronic Publication: </i>2025 Aug 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101598241 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2213-1787 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222131779%22">22131779 </searchLink><i>NLM ISO Abbreviation: </i>JACC Heart Fail <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40857999
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jchf.2025.102590
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102590
    Titles:
      – TitleFull: Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lu H
      – PersonEntity:
          Name:
            NameFull: Claggett BL
      – PersonEntity:
          Name:
            NameFull: Vaduganathan M
      – PersonEntity:
          Name:
            NameFull: Desai AS
      – PersonEntity:
          Name:
            NameFull: Jhund PS
      – PersonEntity:
          Name:
            NameFull: Voors AA
      – PersonEntity:
          Name:
            NameFull: Senni M
      – PersonEntity:
          Name:
            NameFull: Zannad F
      – PersonEntity:
          Name:
            NameFull: Pitt B
      – PersonEntity:
          Name:
            NameFull: Shah SJ
      – PersonEntity:
          Name:
            NameFull: Lam CSP
      – PersonEntity:
          Name:
            NameFull: Scheerer MF
      – PersonEntity:
          Name:
            NameFull: Scalise A
      – PersonEntity:
          Name:
            NameFull: Mueller K
      – PersonEntity:
          Name:
            NameFull: Berger M
      – PersonEntity:
          Name:
            NameFull: Goea L
      – PersonEntity:
          Name:
            NameFull: McMurray JJV
      – PersonEntity:
          Name:
            NameFull: Solomon SD
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2025 Oct
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2213-1787
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: JACC. Heart failure
              Type: main
ResultId 1